Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Hanker, 2012, The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy, Ann Oncol, 23, 2605, 10.1093/annonc/mds203 Ledermann, 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, Lancet Oncol, 15, 852, 10.1016/S1470-2045(14)70228-1 Ledermann, 2011, Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer, J Clin Oncol, 29, 3798, 10.1200/JCO.2010.33.5208 Bryant, 2005, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, 434, 913, 10.1038/nature03443 Farmer, 2005, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917, 10.1038/nature03445 Alsop, 2012, BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group, J Clin Oncol, 30, 2654, 10.1200/JCO.2011.39.8545 2011, Integrated genomic analyses of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166 Zhang, 2011, Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer, Gynecol Oncol, 121, 353, 10.1016/j.ygyno.2011.01.020 Dann, 2012, BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer, Gynecol Oncol, 125, 677, 10.1016/j.ygyno.2012.03.006 Ledermann, 2012, Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer, N Engl J Med, 366, 1382, 10.1056/NEJMoa1105535 Ledermann, 2016, Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial, Lancet Oncol, 17, 1579, 10.1016/S1470-2045(16)30376-X Mateo, 2016, An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib, Target Oncol, 11, 401, 10.1007/s11523-016-0435-8 Mirza, 2016, Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, N Engl J Med, 375, 2154, 10.1056/NEJMoa1611310 Swisher, 2017, Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial, Lancet Oncol, 18, 75, 10.1016/S1470-2045(16)30559-9 Matulonis, 2015, Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials, Cancer, 121, 1737, 10.1002/cncr.29082 Wilson, 2017, Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease, Ann Oncol, 28, 727, 10.1093/annonc/mdw663 Dougherty, 2017, Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting, Oncotarget, 8, 43653, 10.18632/oncotarget.17613